Scientific Publications by FDA Staff

Mol Cancer Ther 2012 Jan;11(1):235-43

Targeting interleukin-4 receptor alpha with hybrid peptide for effective cancer therapy.

Yang L, Horibe T, Kohno M, Haramoto M, Ohara K, Puri RK, Kawakami K

Interleukin-4 receptor alpha (IL-4Ralpha) chain is highly expressed on the surface of various human solid tumors. We designed a novel hybrid peptide termed IL-4Ralpha-lytic peptide that targets the IL-4Ralpha chain. The IL-4Ralpha-lytic peptide contains a target moiety to bind to IL-4Ralpha and a cellular toxic lytic peptide that selectively kills cancer cells. The anticancer activity of the IL-4Ralpha-lytic peptide was evaluated in vitro and in vivo. It was found that the IL-4Ralpha-lytic peptide has cytotoxic activity in cancer cell lines expressing IL-4Ralpha, determined by quantitative real-time PCR. The IC(50) ratios of the lytic peptide to the IL-4Ralpha-lytic peptide correlated well with the expression levels of IL-4Ralpha on cancer cells (r = 0.80). In addition, IL-4Ralpha-lytic peptide administered either intratumoraly or intravenously significantly inhibited tumor growth in xenograft model of human pancreatic cancer (BXPC-3) in mice. These results indicate that the IL-4Ralpha-lytic peptide generated in this study has a potent and selective anticancer potential against IL-4Ralpha-positive solid cancers.